Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer

由 Katayama, Ryohei, Kobayashi, Yuka, Friboulet, Luc, Lockerman, Elizabeth. L., Koike, Sumie, Shaw, Alice T., Engelman, Jeffrey A., Fujita, Naoya
發表在 Clin Cancer Res (2014)

Predicting Current Glycated Hemoglobin Values in Adults: Development of an Algorithm From the Electronic Health Record

由 Wells, Brian J, Lenoir, Kristin M, Diaz-Garelli, Jose-Franck, Futrell, Wendell, Lockerman, Elizabeth, Pantalone, Kevin M, Kattan, Michael W
發表在 JMIR Med Inform (2018)

The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies

由 Niederst, Matthew J., Hu, Haichuan, Mulvey, Hillary E., Lockerman, Elizabeth L., Garcia, Angel R., Piotrowska, Zofia, Sequist, Lecia V., Engelman, Jeffrey A.
發表在 Clin Cancer Res (2015)

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

由 Rothenberg, S Michael, Concannon, Kyle, Cullen, Sarah, Boulay, Gaylor, Turke, Alexa B, Faber, Anthony C, Lockerman, Elizabeth L, Rivera, Miguel N, Engelman, Jeffrey A, Maheswaran, Shyamala, Haber, Daniel A
發表在 eLife (2015)

Two novel ALK mutations mediate acquired resistance to the next generation ALK inhibitor alectinib

由 Katayama, Ryohei, Friboulet, Luc, Koike, Sumie, Lockerman, Elizabeth L., Khan, Tahsin M., Gainor, Justin F., Iafrate, A. John, Takeuchi, Kengo, Taiji, Makoto, Okuno, Yasushi, Fujita, Naoya, Engelman, Jeffrey A., Shaw, Alice T.
發表在 Clin Cancer Res (2014)

CDK 4/6 inhibitors sensitize PIK3CA Mutant Breast Cancer to PI3K inhibitors

由 Vora, Sadhna R., Juric, Dejan, Kim, Nayoon, Mino-Kenudson, Mari, Huynh, Tiffany, Costa, Carlotta, Lockerman, Elizabeth L., Pollack, Sarah F., Liu, Manway, Li, Xiaoyan, Lehar, Joseph, Wiesmann, Marion, Wartmann, Markus, Chen, Yan, Cao, Z. Alexander, Pinzon-Ortiz, Maria, Kim, Sunkyu, Schlegel, Robert, Huang, Alan, Engelman, Jeffrey A.
出版 2014

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

由 Awad, Mark M., Katayama, Ryohei, McTigue, Michele, Liu, Wei, Deng, Ya-Li, Brooun, Alexei, Friboulet, Luc, Huang, Donghui, Falk, Matthew D., Timofeevski, Sergei, Wilner, Keith D., Lockerman, Elizabeth L., Khan, Tahsin M., Mahmood, Sidra, Gainor, Justin F., Digumarthy, Subba R., Stone, James R., Mino-Kenudson, Mari, Christensen, James G., Iafrate, A. John, Engelman, Jeffrey A., Shaw, Alice T.
出版 2013

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer

由 Friboulet, Luc, Li, Nanxin, Katayama, Ryohei, Lee, Christian C., Gainor, Justin F., Crystal, Adam S., Michellys, Pierre-Yves, Awad, Mark M., Yanagitani, Noriko, Kim, Sungjoon, Pferdekamper, AnneMarie C., Li, Jie, Kasibhatla, Shailaja, Sun, Frank, Sun, Xiuying, Hua, Su, McNamara, Peter, Mahmood, Sidra, Lockerman, Elizabeth L., Fujita, Naoya, Nishio, Makoto, Harris, Jennifer L., Shaw, Alice T., Engelman, Jeffrey A.
出版 2014

Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third Generation EGFR Inhibitor

由 Piotrowska, Zofia, Niederst, Matthew J., Karlovich, Chris A., Wakelee, Heather A., Neal, Joel W., Mino-Kenudson, Mari, Fulton, Linnea, Hata, Aaron N., Lockerman, Elizabeth L., Kalsy, Anuj, Digumarthy, Subba, Muzikansky, Alona, Raponi, Mitch, Garcia, Angel R., Mulvey, Hillary E., Parks, Melissa K., DiCecca, Richard H., Dias-Santagata, Dora, Iafrate, A. John, Shaw, Alice T., Allen, Andrew R., Engelman, Jeffrey A., Sequist, Lecia V.
發表在 Cancer Discov (2015)

Patient-derived Models of Acquired Resistance Can Identify Effective Drug Combinations for Cancer

由 Crystal, Adam S., Shaw, Alice T., Sequist, Lecia V., Friboulet, Luc, Niederst, Matthew J., Lockerman, Elizabeth L., Frias, Rosa L., Gainor, Justin F., Amzallag, Arnaud, Greninger, Patricia, Lee, Dana, Kalsy, Anuj, Gomez-Caraballo, Maria, Elamine, Leila, Howe, Emily, Hur, Wooyoung, Lifshits, Eugene, Robinson, Hayley E., Katayama, Ryohei, Faber, Anthony C., Awad, Mark M., Ramaswamy, Sridhar, Mino-Kenudson, Mari, Iafrate, A. John, Benes, Cyril H., Engelman, Jeffrey A.
發表在 Science (2014)

Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations

由 Ahronian, Leanne G., Sennott, Erin M., Van Allen, Eliezer M., Wagle, Nikhil, Kwak, Eunice L., Faris, Jason E., Godfrey, Jason T., Nishimura, Koki, Lynch, Kerry D., Mermel, Craig H., Lockerman, Elizabeth L., Kalsy, Anuj, Gurski, Joseph M., Bahl, Samira, Anderka, Kristin, Green, Lisa M., Lennon, Niall J., Huynh, Tiffany G., Mino-Kenudson, Mari, Getz, Gad, Dias-Santagata, Dora, Iafrate, A. John, Engelman, Jeffrey A., Garraway, Levi A., Corcoran, Ryan B.
發表在 Cancer Discov (2015)

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

由 Niederst, Matthew J., Sequist, Lecia V., Poirier, John T., Mermel, Craig H., Lockerman, Elizabeth L., Garcia, Angel R., Katayama, Ryohei, Costa, Carlotta, Ross, Kenneth N., Moran, Teresa, Howe, Emily, Fulton, Linnea E., Mulvey, Hillary E., Bernardo, Lindsay A., Mohamoud, Farhiya, Miyoshi, Norikatsu, VanderLaan, Paul A., Costa, Daniel B., Jänne, Pasi A., Borger, Darrell R., Ramaswamy, Sridhar, Shioda, Toshi, Iafrate, Anthony J., Getz, Gad, Rudin, Charles M., Mino-Kenudson, Mari, Engelman, Jeffrey A.
發表在 Nat Commun (2015)

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

由 Hata, Aaron N, Niederst, Matthew J, Archibald, Hannah L, Gomez-Caraballo, Maria, Siddiqui, Faria M, Mulvey, Hillary E, Maruvka, Yosef E, Ji, Fei, Bhang, Hyo-eun C, Radhakrishna, Viveksagar Krishnamurthy, Siravegna, Giulia, Hu, Haichuan, Raoof, Sana, Lockerman, Elizabeth, Kalsy, Anuj, Lee, Dana, Keating, Celina L, Ruddy, David A, Damon, Leah J, Crystal, Adam S, Costa, Carlotta, Piotrowska, Zofia, Bardelli, Alberto, Iafrate, Anthony J, Sadreyev, Ruslan I, Stegmeier, Frank, Getz, Gad, Sequist, Lecia V, Faber, Anthony C, Engelman, Jeffrey A
發表在 Nat Med (2016)

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

由 Gainor, Justin F., Dardaei, Leila, Yoda, Satoshi, Friboulet, Luc, Leshchiner, Ignaty, Katayama, Ryohei, Dagogo-Jack, Ibiayi, Gadgeel, Shirish, Schultz, Katherine, Singh, Manrose, Chin, Emily, Parks, Melissa, Lee, Dana, DiCecca, Richard H., Lockerman, Elizabeth, Huynh, Tiffany, Logan, Jennifer, Ritterhouse, Lauren L., Le, Long P., Muniappan, Ashok, Digumarthy, Subba, Channick, Colleen, Keyes, Colleen, Getz, Gad, Dias-Santagata, Dora, Heist, Rebecca S., Lennerz, Jochen, Sequist, Lecia V., Benes, Cyril H., Iafrate, A. John, Mino-Kenudson, Mari, Engelman, Jeffrey A., Shaw, Alice T.
發表在 Cancer Discov (2016)

Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM

由 Song, Kyung-A, Niederst, Matthew J., Lochmann, Timothy L., Hata, Aaron N., Kitai, Hidenori, Ham, Jungoh, Floros, Konstantinos V., Hicks, Mark A., Hu, Haichuan, Mulvey, Hillary E., Drier, Yotam, Heisey, Daniel A.R., Hughes, Mark T., Patel, Neha U., Lockerman, Elizabeth L., Garcia, Angel, Gillepsie, Shawn, Archibald, Hannah L., Gomez-Caraballo, Maria, Nulton, Tara J., Windle, Brad E., Piotrowska, Zofia, Sahingur, Sinem E., Taylor, Shirley M., Dozmorov, Mikhail, Sequist, Lecia V., Bernstein, Bradley, Ebi, Hiromichi, Engelman, Jeffrey A., Faber, Anthony C.
發表在 Clin Cancer Res (2017)